Kornimate/medical-research-clean huggingface dataset:
prevalence of lower cross syndrome among female college students and its relation with dysmenorrhea

Conditions: Cross Syndrome

Summary: the purpose of the study is to find out the prevalence of lower cross syndrome among female college students and its relation with dysmenorrhea.

in individuals with lower cross syndrome (lcs), there is often a notable tightness in the hip flexors and the lower back musculature, which is typically accompanied by a corresponding weakness in the abdominal muscles and the gluteus maximus. this imbalance is not merely a matter of discomfort; it fundamentally disrupts the normal distribution of biomechanical forces within the lower back. when the muscles that support the pelvis and spine are not functioning optimally, it can lead to altered movement patterns and increased strain on the lumbar region. the positioning of the uterus can also be adversely affected by this muscular imbalance. anterior or posterior displacement of the uterus can occur as a result of the altered pelvic alignment associated with lcs. this displacement can create additional tension within the surrounding soft tissues and muscles, leading to a cascade of physiological responses. one notable consequence of this tension is the excessive secretion of prostaglandins, which are hormone-like substances that play a key role in the regulation of inflammation and pain. elevated levels of prostaglandins are often linked to dysmenorrhea, or painful menstruation, which can further exacerbate discomfort and impact the daily lives of those affected. to date, there is only one previous study in india investigating the prevalence of lcs among female college students and its relation with dysmenorrhea. there is lack of literature evidence, which can show the prevalence of lcs among female college students in egypt. so, this study aims to fill a critical gap in existing literature by providing valuable insights into the prevalence and associated factors of lcs in this population in egypt.

Eligibility criteria:
inclusion criteria: * they were virgin, healthy female college students. * they had regular menstruation (3-8 days in duration, with 21-35 days in-between). * their ages ranged from 18 to 25 years old. * their body mass index (bmi) will range from 18 to 24.9 kg/m2. * their waist- hip ratio was less than (0.8). exclusion criteria: * history of back or lower limb surgery * trauma to back or lower extremity * rheumatoid arthritis * spinal deformity such as kyphosis and scoliosis. * any neurological disease * uncooperative volunteers.
study of using long acting antihistamine to treat opioid induced itching

Conditions: Pruritus

Summary: the purpose of this study is determine if long acting antihistamine like cetirizine can help with itching induced by opioid pain medications.


Eligibility criteria:
inclusion criteria: * children age 6-18yrs on opioids who develop pruritus and are willing to participate in the study exclusion criteria: * children with history of chronic urticaria * children with other chronic pruritic condition like eczema, contact dermatitis, psoriasis * children with known hypersensitivity to cetirizine/zyrtec * children on h1 antihistamine like diphenhydramine, hydroxyzine, cetirizine, loratadine, fexofenadine, chlorpheniramine within the last 7days prior to randomization * children who have received ondansetron within 24hrs prior to randomization * children who are on tricyclic antidepressants * children who are unwilling or unable to swallow the capsule. * children with chronic liver or kidney disease
the detection of circulating tumor cells (ctcs) in breast cancer with a novel in vivo device

Conditions: Circulating Tumor Cells.Breast

Summary: the gilupi cellcollector® is the first in vivo ctc isolation product worldwide which is ce approved. application data of cellcollector in china is not available now. the purpose of this clinical trial is to confirm the validation and safety of cellcollector in chinese patients.


Eligibility criteria:
inclusion criteria: * metastasis breast cancer confirmed with imaging examination * have agreed to undergo ctc analysis in vivo; * ecog：0-2 exclusion criteria: * non-metastasis breast cancer
outcome indicators of non-surgical therapy of peri-implantitis

Conditions: Peri-Implantitis; Infections

Summary: objectives: to identify patient and implant indicators influencing the non-surgical therapeutic outcomes of peri-implantitis at 6-months follow-up. material and methods: this prospective cohort study included patients with at least one implant diagnosed with peri-implantitis according to the 2017 world workshop. non-surgical therapy consisted in a mechanical debridement of the peri-implant pockets combined with the metronidazole 500 mg every 8 hours during 7 days. at baseline and at 6 months, clinical and radiographic variables were collected to calculate the success of the therapy. the influence of patient and implant/prosthetic variables on disease resolution were assessed trough simple and multiple logistic regression analysis at patient and implant level using generalized estimation equations models.


Eligibility criteria:
inclusion criteria: * subjects over 18 years old * at least one implant in function for more than 1 year diagnosed with peri-implantitis following the case definition of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions (berglundh et al., 2018). exclusion criteria: * previous surgical therapy of peri-implantitis * allergy to metronidazole * clinical implant mobility * pregnancy or lactating females * previous non-surgical treatment (i.e., submucosal debridement) of the affected implants at least 12 months before * use of systemic antibiotics during the previous 3 months as well as use of systemic antibiotics for endocarditis prophylaxis, * systemic diseases, medications, or conditions that may compromise wound healing and influence the outcome of the therapy.
comparision of the clinical efficacy of different desensitizing toothpastes

Conditions: Dentine Hypersensitivity

Summary: dentin hypersensitivity is a common problem in society. untreated hypersensitivity affects the patient's quality of life, complicates plaque control and increases the risk of caries and periodontal disease. this study aimed to evaluate the clinical efficacy of desensitizing toothpastes containing sodium fluoride, stannous fluoride, nano-hydroxyapatite, 8% arginine and calcium carbonate. fourty eight patients with at least two teeth with positive responses to air and mechanical stimulus were included in the study and were divided into four groups. sodium fluoride (colgate®, cavity protection) in group a, stannous fluoride (oral b® gum calm \& sensitivity) in group b, nano-hydroxyapatite (apacare®) in group c and 8% arginine and calcium carbonate combination in group d (colgate® sensitive pro- relieftm) were used by the patients continuously for 16 weeks. dentin hypersensitivity, by using vas and shiff scores and periodontal parameters were evaluated at baseline, 2nd week, 4th week and last 16th week.


Eligibility criteria:
inclusion criteria: * dentin hypersensitivity complaints * systemically healthy * not during pregnancy \& lactation * no sensitivity treatment in the last 6 months * forty-eight patients with positive response to vas and schiff tests were included. exclusion criteria: people who have; * any systemic disease * take regular medication for any other reason * undergone periodontal surgery within the last 6 months, * history of allergy to toothpaste materials, * active caries, restoration and/or bridge on the sensitive tooth, * orthodontic appliances,

Keywords: dentin hypersensitivity toothpaste fluoride arginine nano-hydroxyapatite
post-exercise insulin reductions in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent type 1 diabetes individuals experiencing hypoglycaemia.


Eligibility criteria:
inclusion criteria: * t1dm, * male, * basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart), * hba1c \< 9.9%, * aged 18-50. exclusion criteria: * hba1c \> 10%, * not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart), * aged \ 50.

Keywords: t1dm, exercise
semibranch registry - retrospective

Conditions: Aortic Aneurysm; Endovascular Aortic Repair; Stent-Graft Endoleak

Summary: the goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.

the main question it aims to answer are: * patency of the semibranch * feasibility of the technique regarding cannulation and stentgrafting

Eligibility criteria:
* patient has been treated with the semibranch stentgraft * patient is over 18 years old
efficacy and safety of valdecoxib and naproxen in treating the signs and symptoms of rheumatoid arthritis (ra) in a severe rheumatoid arthritis patients

Conditions: Arthritis, Rheumatoid

Summary: the objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (qd) or naproxen 500 mg twice daily (bid) versus placebo, and to assess the efficacy of valdecoxib 10 mg qd versus naproxen 500 mg bid, in treating the signs and symptoms of rheumatoid arthritis (ra) in a severe rheumatoid arthritis population.


Eligibility criteria:
inclusion criteria: * a diagnosis of severe rheumatoid arthritis (ra) for at least 6 months * the rheumatoid arthritis must have been treated with a stable regimen including a non-steroidal anti-inflammatory drug (nsaid), as well as methotrexate for at least 12 weeks -or- an nsaid (for at least 12 weeks plus a tumor necrosis factor inhibitor (i.e., adalimumab \[humira®\] for a minimum of 5 doses on a regular schedule, etanercept \[enbrel®\] for 6 weeks, infliximab (remicade®) for 3 doses and currently on a stable regimen of infusions not more than every 8 weeks) exclusion criteria: * a diagnosis of any other inflammatory arthritis or a secondary, noninflammatory type of arthritis (eg, osteoarthritis (oa) or fibromyalgia) that, in the investigator's opinion, was symptomatic enough to interfere with the evaluation of the effect of valdecoxib on the patient's primary diagnosis of rheumatoid arthritis were excluded from the study

Keywords: valdecoxib, severe rheumatoid arthritis
impact of timing of neuraxial analgesia on obstetric, anesthesiologic and neonatal outcomes in induced labour

Conditions: Labour Analgesia, Epidural Anaesthesia; Duration of Labour; Labor, Induced

Summary: the aim of this observational study is to assess the effect of early labour analgesia on obstetric and neonatal outcomes in induced labour in primiparous women with a full-term pregnancy whose labour was induced with a cook balloon or prostaglandins. it aims to answer whether early labour analgesia (\ 4 centimetres).


Eligibility criteria:
inclusion criteria: * age \> 18 years; * primipara; * single pregnancy; * gestational age \> 36 weeks; * induced labour with bishop score \< 6; * cervical dilatation at start of analgesia ≤ 6 cm; * asa class 2. exclusion criteria: * endouterine fetal death; * anhydramnios: * trial labour after caesarean section; * cardiotocogram class ≥2 before start of analgesia; * third trimester bleeding; * patient refusal; * inability to understand informed consent.

Keywords: neuraxil analgesia induced labour
comparison of pre-operative eus guided and intra-operative direct portal vein pressure measurement in pretransplant cirrhotics

Conditions: Liver Cirrhosis

Summary: direct portal pressure measurement under eus-guidance (eus-ppm) is a promising alternative to conventional indirect hepatic venous pressure gradient (hvpg). in patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (pv) pressure requires intra-operative portal vein inflow modulation (pim). this pilot study aims to assess correlation between eus-ppm with direct intra-operative portal pressure measurement (io-ppm).


Eligibility criteria:
inclusion criteria: * liver cirrhosis patients scheduled for liver transplant for the standard indications within next 24- 48 hours will be included. exclusion criteria: * severe ascites not amenable for tapping * history of blood thinner consumption within last 5 days * active duodenal ulcerations
study to explore the mechanism of acquired immune escape in participants with metastatic cancer progressing on cpi therapy

Conditions: Neoplasms

Summary: the purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from cpi treatment of metastatic cancer or hematologic malignancies.


Eligibility criteria:
inclusion criteria: * response assessment of complete response (cr), partial response (pr), or long-term stable disease (sd) for \>6 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed cpi or through participation in a roche/genentech cpi clinical trial. * availability of tissue sample. exclusion criteria: * pregnant, lactating, or intending to become pregnant during the study. * participants receiving cpi treatment as part of a non-roche/genentech clinical trial.

Keywords: metastatic cancer
changing habits in anorexia nervosa: novel treatment development

Conditions: Anorexia Nervosa

Summary: the investigators are examining what types of psychotherapy are most helpful for patients as they undergo weight restoration treatment for anorexia nervosa. in this study, patients who are receiving care on our inpatient unit will also receive 4 weeks of one two types of psychotherapy: supportive psychotherapy or regulation emotions and changing habits.

patients will be receiving specialized inpatient treatment for anorexia nervosa on the eating disorders unit at the new york state psychiatric institute, where care is provided free of charge. study procedures will begin after one week of acclimating to the inpatient unit. patients will be randomly assigned to receive either supportive psychotherapy (focused on the transition to the inpatient unit) or reach (focused on changing routines or habits that have become part of the eating disorder). each treatment consists of 12-sessions, delivered 2-3 times per week. before and after treatment, patients will be asked to participate in interviews, questionnaires, and a lunch meal.

Eligibility criteria:
inclusion criteria: * dsm5 diagnosis of anorexia nervosa * age\>= 18 * medically stable * able to provide informed consent exclusion criteria: * other psychiatric disorder requiring acute treatment * serious medical illness * antipsychotic medication * severe cognitive impairment

Keywords: eating disorders psychotherapy anorexia nervosa treatment
impact of a one-month long detoxification diazepam treatment on early alcohol relapse

Conditions: Alcoholism

Summary: alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (aws) in case of alcohol drinking cessation. diazepam is the reference medication for preventing or treating aws. the recommended average diazepam treatment duration is usually around one week, and this duration is generally not considered to impact the subsequent relapse rate in alcohol drinking. however, several previous studies have found that patients experienced frequent anxious symptoms during the weeks following detoxification. such symptoms may foster early relapse in alcohol drinking. furthermore, it has been suggested that this anxiety could pertain to late withdrawal symptoms. the diama study hypothesizes that extending the diazepam detoxification treatment to one month can significantly reduce the cumulated relapse rate in alcohol drinking over the three following months.

* inclusion at day 5 of the outpatient alcohol detoxification procedure * randomization in two arms: 1) "10 day - diazepam"; and 2) "30 day - diazepam" * tapering of diazepam over the 10 days following the beginning of the detoxification procedure in the first arm; tapering of diazepam over the 30 days following the beginning of the detoxification procedure in the second arm. * 3-month-long follow-up after detoxification. objective of maintaining abstinence from alcohol. no use of additional anticraving drug. standardised psychotherapeutic support based on the brenda model. * longitudinal recording of alcohol consumption using the alcohol timeline follow-back method. * assessment of craving (obsessive-compulsive drinking scale) and anxiety (state-trait anxiety inventory; hamilton anxiety rating scale) at days 5 (baseline), 15, 30, 60 and 90 (final assessment).

Eligibility criteria:
inclusion criteria: * dsm-iv-tr criteria for alcohol dependence * diazepam-based outpatient detoxification procedure started 5 days prior to inclusion exclusion criteria: * contraindication for outpatient detoxification * occurrence of delirium tremens or seizures during the pre-inclusion period * contraindication for using diazepam * any other dsm-iv-tr criteria for substance abuse or dependence in the preceding year (except from tobacco) * concurrent axis-i psychiatric disorder * concurrent neurological pathology or cognitive impairment * concurrent social risk, i.e., homelessness or social isolation * liver failure, cancer, or significant breathing disorder

Keywords: alcohol-dependence relapse detoxification diazepam benzodiazepines anxiety
a bioequivalence study of hetrombopag in healthy subjects

Conditions: Sever Aplastic Anaemia

Summary: this study consists of two parts. part 1 is a pilot be study, and part 2 is a pivotal study to demonstrate the bioequivalence of test and reference formulation, both of which adopt a single-center, randomized, open-label, three-period crossover design.


Eligibility criteria:
inclusion criteria: 1. sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions; 2. ability to complete the study as required by the protocol; 3. healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent; 4. body mass index (bmi) within the range of 19 \~ 26 kg /m2 (including 19 and 26); exclusion criteria: 1. allergic constitution; 2. history of drug use, or drug abuse screening positive; 3. alcoholic or often drinkers; 4. history of deep vein thrombosis, or any other thromboembolic event; 5. a clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
nerve grafting technique to restore erectile function post radical prostatectomy

Conditions: Prostate Cancer; Erectile Dysfunction Following Radical Prostatectomy

Summary: a single arm prospective pilot trial evaluating the safety and the 1-year erectile recovery outcomes of patients undergoing a somatic to autonomic nerve grafting procedure for restoration of erectile function in patients who have lost erectile function following radical prostatectomy for prostate cancer. during this study a total of 10 patients who have persistent erectile dysfunction for more than 18 months post prostatectomy will undergo a post radical prostatectomy nerve restoration procedure (prp-nr).

the investigators are proposing a single arm prospective pilot study evaluating the safety and the 1-year erectile recovery outcomes of patients undergoing the prp-nr procedure. a total of 10 patients will undergo the prp-nr procedure, which is a novel nerve grafting procedure which will utilize a graft of the ilioinguial nerve to perform a bilateral end to side connection between the dorsal penile nerve and the corpora cavernosa with the intent to restore erectile function. participants will have a baseline evaluation with iief-5 and sf-mpq questionnaires, and then will have re-evaluation with these questionnaires at their standard of care post operative visits at 4 weeks, 3-, 6-, 12-, 18- and 24- months. post operative safety will be assessed by recording any clinically detected complications during their peri- and post-operative care.

Eligibility criteria:
inclusion criteria: 1. patients with persistent post prostatectomy erectile dysfunction more than 18 months from prostatectomy and which results in the inability to achieve intercourse with the aid of pde5-i medications. 2. patients must have had good pre-prostatectomy erectile function with a baseline iief score of ≥17 on self-reported assessment of historic function. exclusion criteria: 1. patients with previous pelvic radiotherapy 2. patients aged \< 18 years at diagnosis 3. legally incapable patients 4. patients who are unable to complete questionnaires and have no companion to help complete them 5. patients with pre-existing neurologic disease 6. patients with a history of bilateral surgeries for inguinal hernia repair.
periodontal disease and circulatory microbial components

Conditions: Periodontal Disease

Summary: the goal of this project is to study the immune activity of certain proteins present in the blood of patients with severe periodontal disease. periodontal disease (gum disease) is the major cause of tooth loss among adults. moderate to severe periodontal disease is reported to affect 5-15% of american adults. it begins with an infection of the tissues surrounding the teeth, and leads to a worsening inflammatory response. this study will aid in clarifying the way in which gum disease might affect certain systemic diseases.

this project will have two specific goals: 1. identify microorganism components in the serum of patients with severe periodontitis; and 2. characterize the immune regulator activity of periodontitis serum. this proposed feasibility study will then aid in providing the support for an increased sample size and other design requirements for larger, more expanded human clinical trial testing.in this study, forty (40) subjects will be divided into 2 groups: 1) healthy oral status group and 2) severe periodontal disease. patients will be clinically screened using standard periodontal measurements.

Eligibility criteria:
inclusion criteria: * 35 years or older * healthy patients or patients with severe periodontal disease * patients with or without rheumatoid arthritis * patients with at least 20 permanent teeth exclusion criteria: * patients undergoing long-term (over 2 weeks) antibiotic-related therapy 3 months prior to study inclusion * patients receiving periodontal treatment 12 months prior to study inclusion (including cleanings) * patients will be excluded if they receive long-term use of medications known to affect periodontal status such as anti-inflammatory drugs, aspirin and ibuprofen * patients on immunosuppressive therapies, including glucocorticoids or cyclosporines, are excluded from participation in this study (inhalers are allowed) * history of metabolic bone diseases such as rheumatoid arthritis or post-menopausal osteoporosis * pregnant women or women attempting to become pregnant

Keywords: periodontal disease gum disease dental inflammation microorganisms bacteria
the efficacy of oral versus intravenous hypertonic saline administration in runners with exercise-associated hyponatremia

Conditions: Exercise-associated Hyponatremia

Summary: the purpose of the study is to 1) evaluate incidence and primary cause of exercise-associated hyponatremia (eah) in race finishers participating in the western states 100-mile endurance run, 2) determine if the ingestion of oral hypertonic saline (high salt) is as effective as intravenous administration of hypertonic saline to elevate below-normal blood salt concentrations (eah) at the end of the western states endurance run, and 3) determine if oral and intravenous hypertonic saline solutions are equally as effective at reversing mild (without altered mental status) symptoms associated with eah.


Eligibility criteria:
inclusion criteria: * consenting western states 100 race finisher * hyponatremic exclusion criteria: * altered mental status

Keywords: exercise-associated hyponatremia randomized treatment trial endurance runners